Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xeruborbactam and Cefiderocol drug-drug interaction study in healthy volunteers
NCT06547554Phase 1Completed
- Sponsor
- Qpex Biopharma
- Start
- Sep 2024
- Primary completion
- Oct 2025
- Modality
- Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of xeruborbactam in bacterial infection (6 arms), sponsored by Qpex Biopharma. Primary endpoints: Treatment Emergent Adverse Events, Changes from Baseline in Safety Parameters and 8 more. Started Sep 2024; status: completed.
02
Drugs
xeruborbactam
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT06547554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06547554.